期刊文献+

肝硬化腹水的诊断与治疗进展 被引量:27

原文传递
导出
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2006年第11期1733-1736,共4页 Chinese Journal of Practical Internal Medicine
作者简介 E—mail:wanggq@hotmail.com;王贵强,教授,博士生导师,北京大学第一医院感染疾病科主任。兼任中华医学会感染病学分会常委兼秘书,卫生部卫生标准委员会委员,卫生部自然疫源性疾病专家咨询委员等,《中华内科杂志》等10余种核心期刊编委。已在国际核心刊物发表论著14篇,国内核心期刊发表论文50余篇。1996年荣获“第二届全国优秀中青年医学科技之星”称号,曾获国家科技进步三等奖1项。主持卫生部临床学科重点项目“慢性乙型肝炎个体化治疗模式的研究”等。参与中国慢性乙型肝炎防治指南治疗部分的起草工作等。
  • 相关文献

参考文献29

  • 1Reynolds TB.Ascites[J].Clin Liver Dis,2000,4:151-168.
  • 2Rimola A,Garcia-Tsao G,Navasa M,et al.Diagnosis,treatment and prophylaxis of spontaneous bacterial peritonitis:a consensus document.International Ascites Club[J].Hepatology,2000,32:142-153.
  • 3Moore KP,Wong F,Gines P,et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology,2003,38:258-266.
  • 4Dudley F.Management of refractory ascites[J].J Gastroenterol,2004,19:194-199.
  • 5陈炎,陈亚蓓,陶荣芳.全腹腔穿刺放液对肝硬化门静脉血流动力学的影响[J].中国实用内科杂志,2004,24(8):473-475. 被引量:21
  • 6朱雅琪.肝硬化腹水与肝肾综合征发病机制及治疗进展[J].中国实用内科杂志,2004,24(4):250-251. 被引量:9
  • 7Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline,a kappa opioid agonist,in patients with cirrhosis[J].J Hepatol,2000,32:38-42.
  • 8Gerbes AL,Gulberg V,Gines P.Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist:a randomized double-blind multicenter trial[J].Gastroenterology,2003,124(4):933-939.
  • 9Vila MC,Coll S,Sola R,et al.Total paracentesis in cirrhotic patients with tense ascites and dilutional hyponatremia[J].Am J Gastroenterol,1999,94:2219-2223.
  • 10Sola-Vera J,Minana J,Ricart E,et al.Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites[J].Hepatology,2003,37(5):1147-1153.

二级参考文献28

  • 1许其增.治疗性腹腔穿刺放液的再评价[J].实用内科杂志,1993,13(7):430-431. 被引量:9
  • 2[1]Garcia-Tsao G.Current management of the complication of the cirrhosis and portal hypertension.Variceal hemorrhage,ascites and spontaneous bacterial peritonitis.Gastroenterol,2001,120(4):726-748
  • 3[2]Kamath PS,Tyce GM,Miller VM,et al.Endothelin-1 modulate intrahepatic resistance in a rat model of noncirrhotic portal hypertension.Hepatology,1999,30(3):401-407
  • 4[3]Rockey D.The cellular pathogenesis of portal hypertension.Stellate cell contractility.Endothelin and nitric oxide.Hepatology,1997,25(1):2-5
  • 5[4]Chan CC,Wang SS,Lee FY,et al.Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats.Hepatology,2001,33(5):816-820
  • 6[5]Arroyo V,Guevara M,Gines P.Hepatorenal syndrome in cirrhosis:Pathogenesis and treatment.Gastroenterology,2002,122(8):1658-1676
  • 7[6]Rouyon BA,Montano AA,Akriviadis EA,et al.The serum ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites.Ann Intern Med,1992,117(2):215-220
  • 8[7]Rocky DC,Chang JJ.Reduced nitric oxide production by endothelial cells in cirrhotic rat liver endothelial dysfunction in portal hypertension.Gastroenterology,1998,114(2):344-351
  • 9[8]Wong F,Liu P,Blendis L.The mechanism of improved sodium hemeostatis of low-dose losartan in preascitic cirrhosis.Hepatology,2002,45(6):1449-1458
  • 10[9]Martin PV,Gines P,Schrier RW.Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.N Engl J Med,1998,339(1):533-541

共引文献55

同被引文献139

引证文献27

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部